E. Ohman J:or Asset Management 13F: New $3.8M Stake in CAI
Key Points
- E. Ohman J:or Asset Management initiated a new position in Caris Life Sciences, Inc. (CAI) consisting of 125,000 shares valued at approximately $3.83 million, according to an October 22, 2026 regulatory filing.
- The stock recently traded near $32.02, sitting well above its 50-day moving average and about 3.4% below its 52-week high of $33.13.
- Wall Street analysts maintain a consensus buy recommendation on the stock with a mean price target of $32.23 ahead of the company's next earnings report.
Get Caris Life Sciences text alerts
We text you when insiders, Congress, analysts or big funds move on $CAI.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Caris Life Sciences, Inc. alert may contain errors. Disclosures
E. Ohman J:or Asset Management opened a new position in Caris Life Sciences, Inc. (CAI), acquiring 125,000 shares valued at approximately $3.83 million, according to a Form 13F filing on October 22, 2026.
CAI
Caris Life Sciences, Inc.
What Changed in E. Ohman J:or Asset Management's Caris Life Sciences Position
The filing shows the asset manager initiated a brand-new stake in the molecular profiling company during the reported quarter. With zero shares held previously, the addition brought the total holding to 125,000 shares with a reported value of $3,828,750.
Other Institutional Activity in Caris Life Sciences
Other large institutional investors adjusted their holdings in the biotechnology firm during the period. J. H. Whitney Equity Partners VI, LLC reduced its holdings by 6,999,329 shares, ending with 11,256,615 shares worth about $351.99 million. Coatue Management LLC kept its position unchanged at 9,819,992 shares valued at approximately $307.07 million. Braidwell LP grew its holdings by 246,688 shares, ending with 8,256,032 shares worth about $258.17 million. Sixth Street Partners Management Company, L.P. cut its stake by 7,059,452 shares to hold 7,327,041 shares valued at roughly $229.12 million. PointState Capital LP trimmed its position by 531,410 shares, wrapping up the period with 6,828,835 shares worth about $213.54 million.
Caris Life Sciences, Inc. Stock Down 1.0%
Shares recently traded around $32.02, sitting up about 16.1% above their 50-day moving average of $27.57 and roughly 49.9% above their 200-day moving average of $21.36. The stock trades just 3.4% below its 52-week high of $33.13 and up 125.7% from its 52-week low of $14.19.
Recent Earnings
The company posted trailing twelve-month revenue of $989.6 million alongside basic earnings of $1.69 per share. The business is scheduled to release its next financial results on November 4, 2026.
Insider Buying and Selling at Caris Life Sciences, Inc.
Company insiders made several transactions in the months leading up to the filing. Director Jeff L. Vacirca bought 31,050 shares on May 11, 2026, at an average price of $16.15 for a total value of $501,426. On the selling side, President David Baxley Ph.D. Spetzler disposed of 597,212 shares on September 4, 2026, valued at roughly $14.83 million. Officer and Director Brian J. Brille sold 400,000 shares on September 17, 2026, at an average price of $30.33 for a total value of $12.13 million. General Counsel John Russel Denton parted with 7,500 shares on September 22, 2026, at an average price of $31.82 for a total value of $238,626.
Analysts Set New Price Targets
Wall Street firms updated their outlooks on the stock ahead of the filing. On August 6, 2026, Evercore ISI Group maintained its outperform rating while lifting its price target from $25.00 to $26.00. UBS initiated coverage with a neutral rating and a $28.00 price target on September 9, 2026. TD Cowen maintained a buy rating on October 13, 2026, raising its target from $30.00 to $36.00. JP Morgan maintained an overweight rating on October 14, 2026, increasing its price target from $25.00 to $35.00. Canaccord Genuity maintained a hold rating on October 19, 2026, bumping its target from $22.00 to $30.00. Overall, analysts hold a consensus buy recommendation on the stock with a mean price target of $32.23.
About Caris Life Sciences
Caris Life Sciences, Inc. is an Irving, Texas-based artificial intelligence TechBio company operating in the healthcare sector. The firm provides molecular profiling services in the United States and internationally, developing solutions that combine molecular information with artificial intelligence and machine learning algorithms to transform healthcare.
Bottom Line
E. Ohman J:or Asset Management's new stake brings fresh attention to the biotechnology firm as it approaches its upcoming earnings report on November 4, 2026. Market participants will monitor institutional filings and analyst revisions to see if support for the stock continues around current price levels.
Related Filing Alerts
Source: E. Ohman J:or Asset Management's 13F filing on $CAI (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts